Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» heart failure
heart failure
Novartis’ blockbuster heart med Entresto snags FDA approval in larger patient group
Novartis’ blockbuster heart med Entresto snags FDA approval in larger patient group
Fierce Pharma
Novartis
Entresto
heart failure
labeling
FDA
Flag link:
Boehringer, Lilly’s Jardiance ties to match AZ’s Farxiga with heart failure label
Boehringer, Lilly’s Jardiance ties to match AZ’s Farxiga with heart failure label
Pharmaforum
Boehringer Ingelheim
Eli Lilly
Jardiance
FDA
heart failure
fast track
Flag link:
Novartis' heart failure med Entresto wins FDA panel backing for bigger patient group—but just how much bigger?
Novartis' heart failure med Entresto wins FDA panel backing for bigger patient group—but just how much bigger?
Fierce Pharma
Novartis
Entresto
heart failure
heart failure with preserved ejection fraction
Flag link:
Will Vectorious Be Victorious in Heart Failure?
Will Vectorious Be Victorious in Heart Failure?
Medical Devices and Diagnostics Industry
devices
Vectorious Medical Technologicies
breakthrough device
FDA
left atrial pressure sensor
heart failure
Flag link:
AHA 2020 – sotagliflozin wins come too late for Lexicon
AHA 2020 – sotagliflozin wins come too late for Lexicon
EP Vantage
Lexicon Pharmaceuticals
sotagliflozin
AHA
heart failure
chronic kidney disease
Flag link:
AHA 2020 – look out for the omecamtiv fault lines
AHA 2020 – look out for the omecamtiv fault lines
EP Vantage
AHA
Omecamtiv Mecarbil
Amgen
Cytokinetics
heart failure
Flag link:
Boehringer, Yale trial digital tech in heart failure
Boehringer, Yale trial digital tech in heart failure
Pharmaforum
Boehringer Ingelheim
Yale
digital therapeutics
digital health
heart failure
Flag link:
ESC: Merck's Steglatro shows limited promise with heart failure hospitalization data
ESC: Merck's Steglatro shows limited promise with heart failure hospitalization data
Fierce Pharma
Merck
Steglatro
ESC
heart failure
Flag link:
ESC: Novartis' Entresto racks up a heart failure study win—but it's a mixed one
ESC: Novartis' Entresto racks up a heart failure study win—but it's a mixed one
Fierce Pharma
Novartis
Entresto
ESC
heart failure
Flag link:
ESC 2020 – Jardiance joins Farxiga in showing heart failure benefit
ESC 2020 – Jardiance joins Farxiga in showing heart failure benefit
EP Vantage
ESC
Eli Lilly
Boehringer Ingelheim
Farxiga
Jardiance
heart failure
AstraZeneca
Flag link:
Boehringer and Lilly’s Jardiance Hits Mark in Decreasing Risk of Death in Heart Failure
Boehringer and Lilly’s Jardiance Hits Mark in Decreasing Risk of Death in Heart Failure
BioSpace
Boehringer Ingelheim
Eli Lilly
Jardiance
heart failure
diabetes
clinical trials
Flag link:
Novartis' Entresto gains steam with cardiologists despite stinging heart failure trial flop
Novartis' Entresto gains steam with cardiologists despite stinging heart failure trial flop
Fierce Pharma
Novartis
Entresto
heart failure
cardiologists
Flag link:
FDA Grants Breakthrough Designation for Heart Failure Device
FDA Grants Breakthrough Designation for Heart Failure Device
Medical Devices and Diagnostics Industry
VisCardia
VisOne
heart failure
devices
FDA
Flag link:
ACC: Bayer and Merck’s vericiguat leads off virtual meeting with positive phase 3 heart failure data
ACC: Bayer and Merck’s vericiguat leads off virtual meeting with positive phase 3 heart failure data
Fierce Biotech
ACC
Merck
Bayer
heart failure
vericiguat
clinical trials
Flag link:
Upcoming events – Bayer and Merck look to vericiguat, and Akero bets on Nash
Upcoming events – Bayer and Merck look to vericiguat, and Akero bets on Nash
EP Vantage
Bayer
Merck
vericiguat
heart failure
AKR-001
Akero Therapeutics
clinical trials
NASH
Flag link:
AstraZeneca kicks off 2020 with double win in US and China
AstraZeneca kicks off 2020 with double win in US and China
Pharmaforum
AstraZeneca
FDA
Farxiga
heart failure
China
Lokelma
hyperkalemia
Flag link:
Eli Lilly, Boehringer's Jardiance flops heart failure trial, falling behind AZ's Farxiga
Eli Lilly, Boehringer's Jardiance flops heart failure trial, falling behind AZ's Farxiga
Fierce Pharma
Eli Lilly
Boehringer Ingelheim
Jardiance
Farxiga
diabetes
AstraZeneca
heart failure
Flag link:
Hitting the road: AstraZeneca launches tour to highlight link between diabetes and heart failure
Hitting the road: AstraZeneca launches tour to highlight link between diabetes and heart failure
Fierce Pharma
AstraZeneca
diabetes
type 2 diabetes
heart failure
Flag link:
AstraZeneca, Novoheart to Co-Develop New Heart Model
AstraZeneca, Novoheart to Co-Develop New Heart Model
Xconomy
AstraZeneca
Novoheart
heart-in-a-jar
heart failure
Flag link:
AHA: Lilly, Boehringer's Jardiance cuts CV hospitalizations over rival diabetes meds
AHA: Lilly, Boehringer's Jardiance cuts CV hospitalizations over rival diabetes meds
Fierce Pharma
diabetes
AHA
heart failure
Eli Lilly
Boehringer Ingelheim
Jardiance
clinical trials
Flag link:
Pages
1
2
3
4
5
6
7
next ›
last »